We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+59.12%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$8.26B
AUM Growth
+$2.81B
(+52%)
Cap. Flow
+$660M
Cap. Flow
% of AUM
7.99%
Top 10 Holdings %
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$242M |
| 2 |
Shattuck Labs
STTK
|
+$181M |
| 3 |
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
|
+$164M |
| 4 |
AbbVie
ABBV
|
+$133M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$91.4M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$275M |
| 2 |
BioNTech
BNTX
|
+$64.3M |
| 3 |
Boston Scientific
BSX
|
+$54.3M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$50.2M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$37.8M |
Sector Composition
| 1 | Healthcare | 95.01% |
| 2 | Technology | 0.52% |
| 3 | Financials | 0.46% |
| 4 | Consumer Staples | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$350M
| $1.15B | 13.91% |
12,629,737
| – | – |
|
|
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
| $476M | 5.77% |
20,620,490
-2,455,317
| -11% | -$50.2M |
|
|
ALLK
3
DELISTED
Allakos
ALLK
| $373M | 4.52% |
2,667,451
+241,891
| +10% | +$25.2M |
|
4
Beam Therapeutics
BEAM
$3.18B
| $308M | 3.74% |
3,778,262
+451,000
| +14% | +$22.2M |
|
|
IGMS
5
DELISTED
IGM Biosciences
IGMS
| $302M | 3.66% |
3,425,455
| – | – |
|
|
6
Shattuck Labs
STTK
$629M
| $295M | 3.57% |
+5,619,914
| New | +$181M |
|
7
argenx
ARGX
$53.9B
| $270M | 3.27% |
918,307
-70,161
| -7% | -$19.3M |
|
|
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $253M | 3.07% |
4,437,968
-336,950
| -7% | -$20M |
|
|
NVTA
9
DELISTED
Invitae Corporation
NVTA
| $220M | 2.66% |
5,263,309
+5,068,306
| +2,599% | +$242M |
|
10
ADC Therapeutics
ADCT
$160M
| $216M | 2.62% |
6,758,794
+405,700
| +6% | +$13.3M |
|
|
OSH
11
DELISTED
Oak Street Health, Inc.
OSH
| $179M | 2.17% |
2,925,711
+273,300
| +10% | +$14.3M |
|
|
MDVL
12
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $176M | 2.14% |
+234,495
| New | +$164M |
|
13
Kymera Therapeutics
KYMR
$9.33B
| $169M | 2.04% |
2,720,489
-12,171
| -0.4% | -$594K |
|
14
Stoke Therapeutics
STOK
$1.86B
| $166M | 2.01% |
2,686,234
+136,728
| +5% | +$6.27M |
|
15
Replimune Group
REPL
$818M
| $152M | 1.84% |
3,993,399
+662,400
| +20% | +$27.6M |
|
|
16
AbbVie
ABBV
$431B
| $149M | 1.8% |
+1,388,904
| New | +$133M |
|
|
ONEM
17
DELISTED
1Life Healthcare
ONEM
| $144M | 1.75% |
3,309,194
-35,500
| -1% | -$1.21M |
|
18
Scholar Rock
SRRK
$6.43B
| $141M | 1.7% |
2,896,589
-4,300
| -0.1% | -$156K |
|
19
Atara Biotherapeutics
ATRA
$76.3M
| $135M | 1.63% |
274,523
-3,032
| -1% | -$1.4M |
|
20
Gilead Sciences
GILD
$163B
| $133M | 1.61% |
2,288,846
-581,116
| -20% | -$35.1M |
|
21
Zentalis Pharmaceuticals
ZNTL
$339M
| $126M | 1.52% |
2,416,406
-16,002
| -0.7% | -$722K |
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $103M | 1.24% |
9,450,305
+1,138,672
| +14% | +$14M |
|
23
Krystal Biotech
KRYS
$10.3B
| $101M | 1.22% |
1,675,036
+173,091
| +12% | +$8.64M |
|
24
Sanofi
SNY
$104B
| $96.4M | 1.17% |
1,984,690
+241,642
| +14% | +$11.9M |
|
25
Regenxbio
RGNX
$636M
| $96.3M | 1.17% |
2,123,492
-104,674
| -5% | -$3.66M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO